Locally Advanced Pancreatic Adenocarcinoma Clinical Trial
Official title:
A Phase Ⅲ, Randomized Controlled Study to Evaluate the Efficacy and Safety of the Combination of Nab-paclitaxel and Gemcitabine Versus mFOLFIRINOX in Treating Patients With Borderline Reseactable and Locally Advanced Pancreatic Cancer
This is a prospective, single-center, randomized, controlled phase Ⅲ study.
Three hundred patients with borderline resectable and locally advanced pancreatic cancer will be randomized 1:1 (150 :150) to the AG and mFOLFIRINOX chemotherapy groups and to observe the overall survival. The AG regimen: albumin-bound paclitaxel and gemcitabine are given intravenous infusion, repeated every 4 weeks for 1, 8, and 15 days, for a total of 4 to 6 cycles. MFOLFIRINOX: Intravenous oxaliplatin for 2 hours, day 1;Intravenous infusion of calcium formyl tetrahydrofolate (LV) for 2 h, day 1;Irinotecan intravenous infusion is added 30 minutes later for 90 minutes, day 1;Intravenous infusion of 5-fluorouracil (5-FU) continued for 46 hours.Repeat every 2 weeks for a total of 4-6 cycles. After neoadjuvant chemotherapy, the surgery will be evaluated according to the patient's tumor and systemic condition. The first cycle of adjuvant chemotherapy begins 4-8 weeks after radical resection, and the choice of adjuvant chemotherapy regimen depends on the response to neoadjuvant chemotherapy.If neoadjuvant chemotherapy is effective, adjuvant chemotherapy maintains the original regimen.Adjuvant chemotherapy has 4 cycles of treatment. Relevant examinations were performed before and after each cycle of medication to assess safety events, imaging review was performed every 2 cycles during the treatment period and every 3 months during the follow-up period. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05679674 -
Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
|
N/A | |
| Completed |
NCT03673137 -
Phase II/III of Randomized Controlled Clinical Research on IRE Synchronous Chemotherapy for LAPC
|
Phase 2/Phase 3 | |
| Recruiting |
NCT04652206 -
Clinical Trial to Investigate Safety, Tolerability and MTD for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.
|
Phase 1/Phase 2 | |
| Completed |
NCT02394535 -
Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer
|
Phase 1 | |
| Not yet recruiting |
NCT06399172 -
OncoSil Pancreatic Cancer Post-marketing Clinical Registry - Italy
|
||
| Withdrawn |
NCT03536182 -
Trial of Carbon Ion Versus Photon Radiotherapy for Locally Advanced, Unresectable Pancreatic Cancer
|
Phase 3 | |
| Active, not recruiting |
NCT04395469 -
FAZA PET/MRI Pancreas
|
N/A | |
| Active, not recruiting |
NCT01585805 -
Gemcitabine Hydrochloride and Cisplatin With or Without Veliparib or Veliparib Alone in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Recruiting |
NCT05607953 -
Pressure Enabled Intrapancreatic Delivery of SD-101 With Checkpoint Blockade for Locally Advanced Pancreatic Adenocarcinoma
|
Phase 1 | |
| Not yet recruiting |
NCT06381154 -
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT03269526 -
BATs Treatment for Pancreatic Cancer, Phase Ib/II
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT06453486 -
A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment
|
Phase 2 | |
| Recruiting |
NCT05524090 -
PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer
|
||
| Completed |
NCT01342224 -
Immunochemoradiotherapy in Patients With Pancreatic Cancer
|
Phase 1 | |
| Completed |
NCT01278368 -
Effect Of Preoperative Chemotherapy On Short-Term Outcome After Pancreatic Resection
|
N/A | |
| Recruiting |
NCT04172532 -
Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04423731 -
Neoadjuvant Chemotherapy in Borderline Resectable and Locally Advanced Pancreatic Cancer
|
||
| Not yet recruiting |
NCT06272162 -
Locally Advanced Pancreatic Cancer After Systemic Therapy: Ablative MR-guided Radiotherapy
|
N/A | |
| Active, not recruiting |
NCT00669734 -
Vaccine Therapy and Sargramostim in Treating Patients With Pancreas Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
| Recruiting |
NCT04665947 -
First-in-human Study of the Theranostic Pair [68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G in Pancreatic Cancer
|
Early Phase 1 |